COST-EFFECTIVENESS OF IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY (RR) CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) IN ENGLAND

被引：0
|
作者：
Hassan, F. [1 ]
Peng, S. [2 ]
Dorman, E. [2 ]
Sorensen, S. [2 ]
Thompson, G. [1 ]
Lee, J. [1 ]
机构：
[1] Janssen UK, High Wycombe, Bucks, England
[2] Evidera, Bethesda, MD USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.246
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN163
引用
收藏
页码：A441 / A441
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF IBRUTINIB IN ADULT PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE NETHERLANDS
    Welten, H.
    Ignacio, T. J.
    Verheggen, B. G.
    VALUE IN HEALTH, 2016, 19 (07) : A737 - A737
  • [2] COST-EFFECTIVENESS OF IBRUTINIB AND RITUXIMAB FOR THE RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN CHINA
    Yang, F.
    Kumar, A.
    Rojanasarot, S.
    Schommer, J. C.
    Shao, R.
    VALUE IN HEALTH, 2018, 21 : S31 - S31
  • [3] COST-EFFECTIVENESS OF VENETOCLAX AND RITUXIMAB COMBINATION THERAPY VERSUS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL) IN COLOMBIA
    Chacon-Acevedo, K. R.
    Gamboa, O.
    Quitian Reyes, D.
    VALUE IN HEALTH, 2020, 23 : S37 - S37
  • [4] Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Kang, Dong-Won
    Wang, Li
    Short, Nicholas J.
    Ferrajoli, Alessandra
    Wang, Yucai
    Zhou, Shouhao
    Shen, Chan
    PHARMACOECONOMICS, 2024, 42 (04) : 409 - 418
  • [5] Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Dong-Won Kang
    Li Wang
    Nicholas J. Short
    Alessandra Ferrajoli
    Yucai Wang
    Shouhao Zhou
    Chan Shen
    PharmacoEconomics, 2024, 42 : 409 - 418
  • [6] COST-EFFECTIVENESS OF IDELALISIB IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN PORTUGAL
    Silva, M. G.
    Gouveia, M.
    Alarcao, J.
    Fiorentino, F.
    Carda, J.
    Costa, R. M.
    Mariz, J. M.
    Raposo, J.
    Borges, M.
    HAEMATOLOGICA, 2015, 100 : 577 - 577
  • [7] Cost-Effectiveness of Venetoclax and Rituximab Combination Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in Argentina
    Elgart, Jorge Federico
    Glancszpigel, Mariana
    Kanevsky, Diego
    Godar, Maria
    Touliet, Valeria
    Albaytero, Natalia
    BLOOD, 2019, 134
  • [8] COST-EFFECTIVENESS OF IDELALISIB IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN PORTUGAL
    Gouveia, M.
    Silva, M. G.
    Alarcao, J.
    Fiorentino, F.
    Carda, J.
    Costa, R.
    Mariz, J. M.
    Raposo, J.
    Costa, J.
    Borges, M.
    VALUE IN HEALTH, 2015, 18 (07) : A461 - A462
  • [9] Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (RR) chronic lymphocytic leukemia (CLL).
    Rogers, Kerry Anne
    Thompson, Philip A.
    Allan, John Nathan
    Coleman, Morton
    Sharman, Jeff Porter
    Cheson, Bruce D.
    Izumi, Raquel
    Frigault, Melanie M.
    Quah, Cheng Seok
    Raman, Rakesh K.
    Wang, Min Hui
    Kipps, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Burger, Jan A.
    Ferrajoli, Alessandra
    Estrov, Zeev E.
    Borthakur, Gautam M.
    Takahashi, Koichi
    Bose, Prithviraj
    Fowler, Nathan H.
    Kadia, Tapan M.
    Daver, Naval G.
    Konopleva, Marina Y.
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2019, 134
12345